NCT02724540: Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver

NCT02724540
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Liver
Additional Notes: 
Exclusions: Patients who are candidates for surgical resections
https://ClinicalTrials.gov/show/NCT02724540

Comments are closed.

Up ↑